Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic neuropathy is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain.
The Diabetic Neuropathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.
Diabetic Neuropathy Pipeline Drugs Market Segmentation by Targets
Some of the key targets of the Diabetic Neuropathy pipeline drugs market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Heat Shock Protein 90, G Protein Coupled Receptor, Hepatocyte Growth Factor, Interleukin 6 Receptor, Lysophosphatidic Acid Receptor 1, and Mannan Binding Lectin Serine Protease 2.
Diabetic Neuropathy Pipeline Drugs Market Analysis, by Targets
For more Diabetic Neuropathy pipeline drugs market target insights, download a free report sample
Diabetic Neuropathy Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Diabetic Neuropathy pipeline drugs market are Aldose Reductase Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Heat Shock Protein 90 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, G Protein Coupled Receptor Agonist, Hepatocyte Growth Factor Activator, Interleukin 6 Receptor Agonist, Lysophosphatidic Acid Receptor 1 Antagonist, and Mannan Binding Lectin Serine Protease 2 Inhibitor.
Diabetic Neuropathy Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanism of action insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample
Diabetic Neuropathy Pipeline Drugs Market Segmentation by Routes of Administration
Some of the key routes of administration in the Diabetic Neuropathy pipeline drugs market are oral, topical, subcutaneous, intravenous, intramuscular, sublingual, and transdermal.
Diabetic Neuropathy Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample
Diabetic Neuropathy Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Diabetic Neuropathy pipeline drugs market are small molecule, monoclonal antibody, gene therapy, peptide, protein, and recombinant protein.
Diabetic Neuropathy Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample
Diabetic Neuropathy Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Diabetic Neuropathy pipeline drugs market are Praetego Inc, Glycadia Inc, Korea United Pharm Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Releviate Therapeutics, Zhejiang Pharmaceutical Co Ltd, Achelios Therapeutics Inc, Applied Therapeutics Inc, and Beijing Tide Pharmaceutical Co Ltd.
Diabetic Neuropathy Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the Diabetic Neuropathy pipeline drugs market, download a free report sample
Diabetic Neuropathy Pipeline Drugs Market Report Overview
Key Targets | Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Heat Shock Protein 90, G Protein Coupled Receptor, Hepatocyte Growth Factor, Interleukin 6 Receptor, Lysophosphatidic Acid Receptor 1, and Mannan Binding Lectin Serine Protease 2 |
Key Mechanisms of Action | Aldose Reductase Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Heat Shock Protein 90 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, G Protein Coupled Receptor Agonist, Hepatocyte Growth Factor Activator, Interleukin 6 Receptor Agonist, Lysophosphatidic Acid Receptor 1 Antagonist, and Mannan Binding Lectin Serine Protease 2 Inhibitor |
Key Routes of Administration | Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Sublingual, and Transdermal |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Gene Therapy, Peptide, Protein, and Recombinant Protein |
Leading Companies | Praetego Inc, Glycadia Inc, Korea United Pharm Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Releviate Therapeutics, Zhejiang Pharmaceutical Co Ltd, Achelios Therapeutics Inc, Applied Therapeutics Inc, and Beijing Tide Pharmaceutical Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- Reviews of pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals LLC
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Ono Pharmaceutical Co Ltd
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Releviate Therapeutics
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Diabetic Neuropathy pipeline drugs market?
Some of the key targets of the Diabetic Neuropathy pipeline drugs market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Heat Shock Protein 90, G Protein Coupled Receptor, Hepatocyte Growth Factor, Interleukin 6 Receptor, Lysophosphatidic Acid Receptor 1, and Mannan Binding Lectin Serine Protease 2.
-
What are the key mechanisms of action of the Diabetic Neuropathy pipeline drugs market?
Some of the key mechanisms of action of the Diabetic Neuropathy pipeline drugs market are Aldose Reductase Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Heat Shock Protein 90 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, G Protein Coupled Receptor Agonist, Hepatocyte Growth Factor Activator, Interleukin 6 Receptor Agonist, Lysophosphatidic Acid Receptor 1 Antagonist, and Mannan Binding Lectin Serine Protease 2 Inhibitor.
-
What are the key routes of administration in the Diabetic Neuropathy pipeline drugs market?
Some of the key routes of administration in the Diabetic Neuropathy pipeline drugs market are oral, topical, subcutaneous, intravenous, intramuscular, sublingual, and transdermal.
-
What are the key molecule types in the Diabetic Neuropathy pipeline drugs market?
The molecule types in the Diabetic Neuropathy pipeline drugs market are small molecule, monoclonal antibody, gene therapy, peptide, protein, and recombinant protein.
-
Which are the leading companies in the Diabetic Neuropathy pipeline drugs market?
Some of the leading companies in the Diabetic Neuropathy pipeline drugs market are Praetego Inc, Glycadia Inc, Korea United Pharm Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Releviate Therapeutics, Zhejiang Pharmaceutical Co Ltd, Achelios Therapeutics Inc, Applied Therapeutics Inc, and Beijing Tide Pharmaceutical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.